In patients with a range of epithelial cancers, predominantly non-small-cell lung cancer and renal cell carcinoma, Routy et al. found that an abnormal gut microbiome composition could be responsible for non-response to anti-PD-1 immunotherapy [29]. This evidence concerns the gene PDCD1 and hereditary clear cell renal cell carcinoma.